Spots Global Cancer Trial Database for nk cell therapy
Every month we try and update this database with for nk cell therapy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Nk Cell Therapy for Recurrent Glioblastoma Multiform Patients | NCT05108012 | Glioblastoma Mu... Recurrent Gliob... | NK cell therapy | 3 Years - 60 Years | Royan Institute | |
| FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors | NCT03319459 | HER2 Positive G... Colorectal Canc... Head and Neck S... EGFR Positive S... Advanced Solid ... HER2-positive B... Hepatocellular ... Non Small Cell ... Renal Cell Carc... Pancreatic Canc... Melanoma | FATE-NK100 Cetuximab Trastuzumab | 18 Years - | Fate Therapeutics | |
| ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors | NCT04319757 | Locally Advance... Metastatic Canc... Solid Tumor HER2-positive G... HER2-positive M... | ACE1702 Cyclophosphamid... Fludarabine | 18 Years - | Acepodia Biotech, Inc. | |
| Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM) | NCT04395092 | Acute Myeloid L... Myelodysplastic... | K-NK002 Conditioning Re... HaploBMT | 18 Years - 65 Years | Kiadis Pharma | |
| Induced-T Cell Like NK Cellular Immunotherapy for Cancer Lack of MHC-I | NCT03882840 | Anti-cancer Cel... T Cell and NK C... | NK cell therapy | 18 Years - | Second Affiliated Hospital of Guangzhou Medical University | |
| Induced-T Cell Like NK Cellular Immunotherapy for Cancer Lack of MHC-I | NCT03882840 | Anti-cancer Cel... T Cell and NK C... | NK cell therapy | 18 Years - | Second Affiliated Hospital of Guangzhou Medical University | |
| FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | NCT03841110 | Advanced Solid ... Lymphoma Gastric Cancer Colorectal Canc... Head and Neck C... Squamous Cell C... EGFR Positive S... HER2-positive B... Hepatocellular ... Small Cell Lung... Renal Cell Carc... Pancreas Cancer Melanoma NSCLC Urothelial Carc... Cervical Cancer Microsatellite ... Merkel Cell Car... | FT500 Nivolumab Pembrolizumab Atezolizumab Cyclophosphamid... Fludarabine IL-2 | 18 Years - | Fate Therapeutics | |
| ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors | NCT04319757 | Locally Advance... Metastatic Canc... Solid Tumor HER2-positive G... HER2-positive M... | ACE1702 Cyclophosphamid... Fludarabine | 18 Years - | Acepodia Biotech, Inc. | |
| Induced-T Cell Like NK Cellular Immunotherapy for Cancer Lack of MHC-I | NCT03882840 | Anti-cancer Cel... T Cell and NK C... | NK cell therapy | 18 Years - | Second Affiliated Hospital of Guangzhou Medical University | |
| Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM) | NCT04395092 | Acute Myeloid L... Myelodysplastic... | K-NK002 Conditioning Re... HaploBMT | 18 Years - 65 Years | Kiadis Pharma |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
